ASBM Submits Comments on Minnesota Health Plan Legislation

November 3, 2022

On November 3rd, ASBM submitted comments to the Minnesota Department of Commerce on two mandated health benefit bills, as part of a public comment period. The first proposal was SF 990, mandating coverage of multiple biologic products, which ASBM opposed. ASBM had previously led patient advocacy organization opposition to the measure last summer. From the comment letter:  […]

Read More

ASBM/Ohio State University Biosimilars CE Course Adds New Module on Patient Perspectives

November 1, 2022

In October, ASBM recorded the latest entry in its ongoing continuing education (CE) series in partnership with the Ohio State University College of Pharmacy. This course module, entitled “Patient Perspectives on Biosimilars”, represents part 6 of the 7-part series covering a wide range of biosimilar policy issues. In this module, participants will hear different perspectives from the […]

Read More

ASBM Physician Survey Featured in Oncology Journal

October 25, 2022

ASBM’s recent survey of 401 U.S. physicians was featured in the October issue of the journal Oncology Practice Management. The article discussed a poster presentation given by ASBM Chairman Ralph McKibbin, MD, FACP, FACG, AGAF at the Drug Information Association Global Annual Meeting (DIA 2022) on June 20th, in Chicago, IL. View the poster here.  The survey findings consistently […]

Read More

Amgen Releases Full 2022 Biosimilar Trends Report

October 20, 2022

In October, Amgen released its full 2022 Biosimilar Trends Report. The report’s findings had been previewed earlier this year by Amgen’s Global Biosimilars Commercial Lead, Chad Pettit at a June 29th webinar hosted by ASBM and GaBI Journal. View the webinar “Key Factors for Successful Uptake of Biosimilar Markets” here. Read GaBI Journal’s Meeting Report here.  The full report […]

Read More

ASBM’s Schneider Discusses Pharmacist, PBM Role at National Policy & Advocacy Summit on Biologics

October 19, 2022

On October 19th, ASBM Advisory Board Chair Philip Schneider participated in the 7th Annual National Policy & Advocacy Summit on Biologics, The event was hosted in Washington, DC by the Biologics Prescribers Collaborative and was also streamed online. Professor Schneider appeared on the opening panel discussion entitled “The Emerging Biologics Landscape”, which also featured Chad Pettit, Executive Director […]

Read More

ASBM Presents at WHO 75th INN Consultation

October 18, 2022

On October 18th, ASBM participated in the World Health Organization’s 75th Consultation on International Non-proprietary Names (INN) for Pharmaceutical Substances, held in Geneva, Switzerland. This was the nineteenth INN Consultation in which ASBM has participated. ASBM was represented by Executive Director Michael Reilly, Esq., and Advisory Board Chair Philip Schneider, MS, FASHP. The proceedings at […]

Read More

ASBM, IFA Observe World Sight Day 2022

October 13, 2022

World Sight Day is observed worldwide every year on the second Thursday of October. This World Health Organization-designated day falls on 13 October this year. The purpose of World Sight Day is to increase public awareness about blindness, vision impairment, vision care, and ocular issues. The WHO estimates that 1 billion people worldwide suffer from […]

Read More

ASBM’s Feldman Discusses Biosimilars in 2023 at STAT Forum

October 12, 2022

On October 12, ASBM Immediate Past Chair Madelaine Feldman, MD, FACR participated in a forum held by STAT, entitled “Biosimilars’ Meteoric Moment”. The forum focused on the long-awaited arrival of multiple adalimumab biosimilars in 2023 and asked experts from a variety of fields to speculate on what 2023 holds for the biosimilars market. Speakers included: Madelaine A. […]

Read More

FDA: “Incorrect” to Assume Interchangeables Are More Effective Than Biosimilars

October 10, 2022

As reported in Generics Bulletin October 10th, Dr. Sarah McMullen, India country director for the US Food and Drug Administration underscored that there’s no real distinction in the standards to determine the safety or efficacy for both biosimilars and interchangeable biosimilars, and put forth a “fact check” to dispel the general notion among patients that interchangeables are […]

Read More

American Academy of Ophthalmology Statement on Biosimilar Substitution

October 6, 2022

  AMERICAN ACADEMY OF OPHTHALMOLOGY“‘ POLICY STATEMENT The Use of Biosimilars in Ophthalmic Practice   Background Congress, through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, created an abbreviated approval pathway for biological products that are demonstrated to be biosimilar to or interchangeable with a Food and Drug Administration (FDA)-approved biological product.1 […]

Read More